Psoriasis is a chronic, autoimmune disease that primarily involves the skin. Most of these people living with psoriasis have plaque psoriasis, which is characterised by “plaques”, or raised, red areas of skin covered with a silver or white layer of dead skin cells referred to as “scale”. Psoriatic plaques can appear on any area of the body but most often appear on the scalp, knees, elbows, trunk, and limbs, and the plaques are often itchy and sometimes painful.

Plaque psoriasis patients often have plaques in areas that are difficult to treat such as skin folds (intertriginous regions) or the scalp, which presents a challenge for drug delivery, as the creams and ointments typically used to treat psoriasis on other body areas can be challenging to apply in these areas. Furthermore, skin folds tend to have thinner, more easily irritated skin and are more prone to steroid-related side effects, especially skin atrophy (thinning), striae (stretchmarks) or telangiectasia (spider veins). Even with biologic therapies, plaques on the elbows and knees are often the last areas to resolve.

Mild                psoriasis
0 %
Moderate to severe psoriasis
0 %

People living with psoriasis are generally characterized as mild, moderate, or severe, with approximately 71% experiencing a mild form of the disease and 29% experiencing a moderate-severe form in the US, EU5 and Japan. Source: Decision Resources Group psoriasis report.

Psoriasis is an autoimmune disease 

0 million

Psoriasis is diagnosed in an estimated 13.4 million patients in 2021 in the US, EU5 and Japan.

US: 7.7m patients, EU5: 5.4m patients, Japan: 0.3m patients.
Source: GlobalData, DRG and Publication: Armstrong et al. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. Published online June 30, 2021

Substantial psychosocial impacts of living with psoriasis

The burden of living with psoriasis is often underestimated. In addition to the direct clinical challenges of psoriasis, many patients with plaque psoriasis suffer substantial psychosocial impacts from their disease, including: social stigma, feelings of rejection and shame, guilt, impaired sexual intimacy, discrimination in the workplace, difficulty finding employment or working outside the home, financial hardships, increased work absenteeism and reduced productivity.

Treatment of psoriasis 

Psoriasis can be managed by topical, oral, biological treatments as well as phototherapy. Depending on the severity of the disease, patients and health care professionals choose between these treatment options. However, many physicians and patients express a need for better oral treatments. 

UNION is developing oral orismilast, a next-generation phosphodiesterase type-4 (“PDE4”) inhibitor, for the treatment of psoriasis. 

Read more here

Meet Frederik who has severe psoriasis and learn about his experience with different treatment options.